# Walloon

> Walloon is a VC fund in Namur backing Biotechnology, Health Care and Therapeutics. See 14 investments, check sizes, portfolio. Updated Oct 2026.

- Type: VC Fund
- Location: Namur, Belgium
- Total investments: 14
- Last investment: Mar 2026
- Lead investor: 86%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/company/service-public-de-wallonie
- Website: http://recherche-technologie.wallonie.be/

Walloon is a VC fund in Namur focused on Biotechnology and Health Care. Walloon provides financial services for startups.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 64% |
| Health Care | 4 | 29% |
| Therapeutics | 2 | 14% |
| Pharmaceutical | 2 | 14% |
| Farming | 1 | 7% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 9 | 64% |
| Series A | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 8 | 57% |
| United States | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Genflow Biosciences | GENFLOW is dedicated to the development and commercialization of novel therapeutics targeting aging in dogs and humans. | $396.5K | Grant | Mar 02, 2026 | https://genflowbio.com/ |
| Genflow Biosciences | GENFLOW is dedicated to the development and commercialization of novel therapeutics targeting aging in dogs and humans. | $4.6M | Grant | Jul 17, 2025 | https://genflowbio.com/ |
| BiocSol | BiocSol focus on sustainable microbial-based crop protection. |  | Grant | Feb 03, 2025 |  |
| Genflow Biosciences | GENFLOW is dedicated to the development and commercialization of novel therapeutics targeting aging in dogs and humans. | $413.1K | Grant | May 30, 2024 | https://genflowbio.com/ |
| Hyloris Pharmaceuticals | Hyloris Pharmaceuticals is an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris Pharmaceuticals develop innovative proprietary products that offer significant advantages compared to currently available alternatives. | $1.1M | Grant | Jun 08, 2023 | https://hyloris.com/ |
| EsoBiotec | EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.EsoBiotec's objective is to enable the human body to fight cancer by delivering 'in vivo' cell engineering to patients. | $3.5M | Grant | Sep 30, 2021 | https://www.esobiotec.com/ |
| EXO Biologics | EXO Biologics is a biotech company developing biopharmaceuticals using extracellular vesicles. | $4.5M | Grant | Feb 05, 2021 | https://www.exobio.be/ |
| ATB Therapeutics | ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients. |  | Grant | Dec 23, 2019 | https://atbtherapeutics.com |
| Convert Pharmaceuticals | Convert Pharmaceuticals is a clinical phase I-IIa drug development company, that is building a proprietary drug pipeline exploiting tumor microenvironment specific factors for therapeutic benefit. Convert’s lead product is a hypoxia activated prodrug (HAP). Hypoxia constitutes a therapeutic obstacle as it promotes the development of resistance toconventional anti-cancer treatments. Convert Pharmaceuticals combines proprietary insights in the tumor microenvironment with expertise in drug and biomarker development to develop effective and well-tolerated HAPs. | $14.9M | Series A | Feb 28, 2018 | http://www.convertpharma.com/ |
| Convert Pharmaceuticals | Convert Pharmaceuticals is a clinical phase I-IIa drug development company, that is building a proprietary drug pipeline exploiting tumor microenvironment specific factors for therapeutic benefit. Convert’s lead product is a hypoxia activated prodrug (HAP). Hypoxia constitutes a therapeutic obstacle as it promotes the development of resistance toconventional anti-cancer treatments. Convert Pharmaceuticals combines proprietary insights in the tumor microenvironment with expertise in drug and biomarker development to develop effective and well-tolerated HAPs. |  | Grant | Feb 28, 2018 | http://www.convertpharma.com/ |

10 of 14 investments shown.

## Co-investors
- [Eurostars](https://shizune.co/investors/profile/eurostars) — VC Fund, 2 deals together
- [Droia Ventures](https://shizune.co/investors/profile/droia) — VC Fund, 1 deal together
- [Meusinvest (Noshaq)](https://shizune.co/investors/profile/meusinvest) — VC Fund, 1 deal together
- [Spinventure](https://shizune.co/investors/profile/spinventure) — VC Fund, 1 deal together
- WBC incubator — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [Wayra](https://shizune.co/investors/profile/wayra) — VC Fund
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund

## FAQ

### What does Walloon invest in?

Walloon invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Grant and Series A stage. Most of the 14 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Walloon last invest?

The most recent investment recorded for Walloon closed in Mar 2026. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co